Global Ophthalmics Partnering Deals Directory 2019: Headline Value, Upfront Payment, Milestone Payments and Royalty Rates Since 2014

DUBLIN, Sept. 6, 2019 /PRNewswire/ -- The "Global Ophthalmics Partnering 2014-2019: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Ophthalmics Partnering 2014 to 2019 provides the full collection of Ophthalmics disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Ophthalmics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Ophthalmics deals.

The report presents financial deal terms values for Ophthalmics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Ophthalmics dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Ophthalmics dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Ophthalmics deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Ophthalmics dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Ophthalmics deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Ophthalmics partnering deals by specific Ophthalmics target announced since 2014. The chapter is organized by specific Ophthalmics therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Ophthalmics partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Ophthalmics partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Ophthalmics technologies and products.

Report Scope

Global Ophthalmics Partnering 2014 to 2019 includes:

• Trends in Ophthalmics dealmaking in the biopharma industry since 2014
• Analysis of Ophthalmics deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Ophthalmics deal contract documents
• Comprehensive access to over 400 Ophthalmics deal records
• The leading Ophthalmics deals by value since 2014
• Most active Ophthalmics dealmakers since 2014

The report includes deals for the following indications: Age-related macular degeneration, Blindness, Cataracts, Conjunctivitis, Diabetic macular edema, Dry eye, Glaucoma, Ocular hypertension, Retinal detachment Retinopathy, Diabetic retinopathy, Uveitis, plus other ophthalmic indications.

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are the sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Ophthalmics dealmaking
2.1. Introduction
2.2. Ophthalmics partnering over the years
2.3. Ophthalmics partnering by deal type
2.4. Ophthalmics partnering by industry sector
2.5. Ophthalmics partnering by stage of development
2.6. Ophthalmics partnering by technology type
2.7. Ophthalmics partnering by therapeutic indication

Chapter 3 -Financial deal terms for Ophthalmics partnering
3.1. Introduction
3.2. Disclosed financials terms for Ophthalmics partnering
3.3. Ophthalmics partnering headline values
3.4. Ophthalmics deal upfront payments
3.5. Ophthalmics deal milestone payments
3.6. Ophthalmics royalty rates

Chapter 4 - Leading Ophthalmics deals and dealmakers
4.1. Introduction
4.2. Most active in Ophthalmics partnering
4.3. List of most active dealmakers in Ophthalmics
4.4. Top Ophthalmics deals by value

Chapter 5 - Ophthalmics contract document directory

5.1. Introduction
5.2. Ophthalmics partnering deals where contract document available

Chapter 6 - Ophthalmics dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Ophthalmics therapeutic target

Appendices

Appendix 1 - Directory of Ophthalmics deals by company A-Z 2014 to 2019
Appendix 2 - Directory of Ophthalmics deals by deal type 2014 to 2019
Appendix 3 - Directory of Ophthalmics deals by stage of development 2014 to 2019
Appendix 4 - Directory of Ophthalmics deals by technology type 2014 to 2019

Companies Mentioned

• 3D-Micromac
• 3M
• 3SBio
• 4D Molecular Therapeutics
• Abbott Laboratories
• Abbvie
• ABL Bio
• Ablynx
• Abpro
• Abzena
• ActiveSite
• Acucela
• Advanced Dosage Forms
• Adverum Biotechnologies
• Aerie Pharmaceuticals
• AffaMed Therapeutics
• AFT Pharmaceuticals
• AGTC
• Aier Eye Hospital Group
• AiVita Biomedical
• AJL Ophthalmic
• Akorn
• Alcon Laboratories
• Aldevron
• Alienware
• Alimera Sciences
• Allegro Ophthalmics
• Allergan
• Allotex
• Alnylam Pharmaceuticals
• Alphaeon
• ALS Association
• Altus Formulation
• Alvotech
• Amarantus BioSciences
• Amarillo Biosciences
• AMD Insight
• American Academy of Ophthalmology
• AmerisourceBergen
• Amneal Pharmaceuticals
• AmorChem
• Andrec
• AnGes MG
• ANI Pharmaceuticals
• Antitope
• AntriaBio
• AOAExcel
• Aptar Pharma
• ArcticDx
• Argentum Pharmaceuticals
• Ascendia Pharmaceuticals
• Astellas Pharma
• Aura Biosciences
• Aurinia Pharmaceuticals
• Avalanche Biotechnologies
• Avedro
• Avellino Labs
• AVEO Oncology
• AXIM Biotechnologies
• AyoxxA Biosystems
• BalGeunSeSang Eye Clinic
• Bausch & Lomb
• Bayer
• Bayer Healthcare
• Benitec Biopharma
• Betaliq
• Beta Therapeutics
• Bio-Tissue
• Biogen
• Biohealth Innovation
• BioInvent
• BioLamina
• BioLight Life Sciences Investments
• BiolineRX
• BioMotiv
• Bionic Sight
• BioTime
• BLP Management
• Bluejay Diagnostics
• Boehringer Ingelheim
• BostonSight
• Breckenridge Pharmaceuticals
• BridgeBio Pharma
• Brigham and Women's Hospital
• BrightFocus Foundation
• Bright Optical
• Brill Pharma
• Broda Technologies
• Buck Institute for Age Research
• C-Bridge Capital
• Caladrius Biosciences
• California Institute for Regenerative Medicine
• California Stem Cell
• Cambridge Research Biochemicals
• Cannabics Pharmaceuticals
• Cardinal Health
• Carl Zeiss Meditec
• Casebia Therapeutics
• Case Western Reserve University
• Catalent Pharma Solutions
• Cataract & Laser Institute
• Celerion
• Cell Care Therapeutics
• Cell Cure Neurosciences
• Cellular Dynamics International
• Cerevast Therapeutics
• Chiesi Farmaceutici
• Children's Hospital Los Angeles
• China Medical System
• Cipla Medpro
• Cirle
• Clarion Medical Technologies
• Clearside Biomedical
• Clover Therapeutics
• CMC Biologics
• Coherus Biosciences
• Columbia Technology Ventures
• Columbia University
• Community College of Philadelphia
• Compact Imaging
• Connecticut Innovations
• Consort Medical
• Contamac
• Cooper-Vemedia
• Corneal Lens
• Corning
• Covenant Surgical Partners
• CRISPR Therapeutics
• CSPC Pharmaceutical Group
• CureVac
• Cyclica
• D. Western Therapeutics Institute
• Dallas Lighthouse for the Blind
• De La Pena Eye Clinic
• DelSiTech
• Department of Defense Hearing Center of Excellence and Vision Center of Excellence
• Diagnos
• Diversified Ophthalmics
• DNX Biopharmaceuticals
• DOSE Medical
• Dr. Agarwal's Eye Hospitals
• DSM
• Duke-NUS Graduate Medical School Singapore
• Duke University
• Durect
• E&B Technologies
• Easton Pharmaceuticals
• Ecole Polytechnique Federale de Lausanne
• Editas Medicine
• Eleven Biotherapeutics
• ElsaLys Biotech
• Envisia Therapeutics
• Essex Bio-Technology
• Eton Pharmaceuticals
• Eupharmed
• Evergaze
• Evotec
• Ewopharma
• Exonate
• Eyegate Pharmaceuticals
• EyeMedics
• Eyeon Therapeutics
• EyePoint Pharmaceuticals
• EyeQ Vision
• Eyevance
• First Insight
• FirstString Research
• Flemish agency for Innovation by Science and Technology
• Flexpoint Sensor Systems
• Florida State University
• Foamix
• Focal
• Focus Laboratories
• Food and Drug Administration (FDA)
• Fortify Therapeutics
• Fortress Biotech
• Foundation Fighting Blindness
• Fujifilm Kyowa Kirin Biologics
• Fuji Pharma
• G-treeBNT
• Galapagos
• Garuda Health Services
• Gauss Surgical
• Genable Technologies
• Genentech
• General Biologicals
• Gensight
• Genzyme
• Gestion Univalor
• GHO Capital
• Gilead Sciences
• Glaucoma Research Foundation
• Glaukos
• Glenmark Pharmaceuticals
• Google
• GrayBug
• Gulf Medical Company
• HanAll Pharmaceuticals
• Hanmi Pharmaceutical
• Harbour Biomed
• Harvard Medical School
• Harvard University
• Healthe Care Australia
• Health Ministry (Italy)
• HealthSouth
• Heidelberg Engineering
• Helvetic Biopharma
• Hitachi Chemical
• Homology Medicines
• Horus Pharma
• Hospira
• HOYA Vision Care
• HPGC Medical
• I-MED Pharma
• i-Optics
• IACTA Pharmaceuticals
• IBM
• IDx
• Ifa Systems
• Imprimis Pharmaceuticals
• Indoco
• Industrial Technology Research Institute
• InMed Pharmaceuticals
• InSite Vision
• Institute of Biophysics
• Integral BioSystems
• Intratus
• Iogen
• Ionis Pharmaceuticals
• Iris Pharma
• ISIS Innovation
• Israeli National Authority for Technological Innovation
• Iveric Bio
• Jackson Laboratory
• Janssen Pharmaceuticals
• Janssen Research & Development
• Jin
• Johns Hopkins University
• Johnson & Johnson Innovation
• Johnson & Johnson Vision
• Kali Care
• KalVista Pharmaceuticals
• KC Pharmaceuticals
• Keen Eye
• Keio Gijuku University
• Knight Therapeutics
• Kobe Kanagawa Eye Clinic
• Kochoptik
• Kubota Pharmaceutical
• Kyoto University
• Laboratoires Thea
• LambdaVision
• Lantheus Holding
• Lee's Pharmaceutical
• Lehigh University
• Leidos
• Leiters
• LensAR
• Leona M and Harry B Helmsley Charitable Trust
• Lin Bioscience
• LKC Technologies
• Lonza
• Lubris BioPharma
• LumiThera
• Lund University
• LV Prasad Eye Institute
• mAbXience
• MacuLogix
• Mannin Research
• Marinomed Biotechnologie
• Massachusetts Eye and Ear Infirmary
• Massachusetts General Hospital
• Mayo Clinic
• McKesson
• McMaster University
• MD Distributor
• MEAgate International
• Mectizan Donation Program
• Medical Research Foundation
• Mediconsult.com
• MedImmune
• Medio-Haus
• MeiraGTx
• Memira Holding
• Merck and Co
• Merck Animal Health
• Merge Healthcare
• Merz
• Meyer Children's Hospital of Florence
• MicroConstants
• Midatech
• Mile High Ophthalmics
• Miloftalmica
• Mimetogen Pharmaceuticals
• Ministry of Health (France)
• Mitacs
• Mitsui Chemicals
• Mobius Therapeutics
• Montgomery County Community College
• Mperia Therapeutics
• Mundipharma
• Mylan Pharmaceuticals
• Nanomerics
• NanoViricides
• Narayana Nethralaya Foundation
• NASA
• National Cancer Institute
• National Center for Advancing Translational Sciences (NCATS)
• National Eye Institute
• National Healthcare Services (NHS)
• National Institute of Neurological Disorders and Stroke
• National Institutes of Health
• National Organization for Rare Disorders
• National Science Foundation
• NEMUS Bioscience
• NeuroVive Pharmaceutical
• Nexus Pharmaceuticals
• Nicox
• Nightstar Therapeutics
• NightstaRx
• Nitto Medic
• NKL
• Notal Vision
• NovaBay Pharmaceuticals
• Novaliq
• NovaMedica
• Novartis
• Novo Nordisk
• NTC
• NuEyes
• Oasis Medical
• Ocata Therapeutics
• Ocugen
• Ocular Therapeutics
• Oculis
• Oculos Clinical Research
• Ocumension Therapeutics
• OcuNexus Therapeutics
• OCuSOFT
• OcuTherix
• Odylia Therapeutics
• Ohr Pharmaceuticals
• OliX Pharmaceuticals
• Omeros
• OmniVision Technologies
• Omron
• ONL Therapeutics
• Ophthalmic Instrument Company
• Ophthotech
• Opsirx Pharmaceuticals
• Opthea
• Optibrand
• OptiKira
• Optima Pharmazeutische
• Optimed
• Optometric Extension Program Foundation
• Optos
• Optovue
• Ora
• Oraya Therapeutics
• Orbis
• Orbit Biomedical
• OrCam
• Oregon Health Sciences University
• Oregon National Primate Research Center
• Osterhout Design Group
• Oxford BioMedica
• Oxurion
• Pacgen Biopharmaceuticals
• Paragon BioTeck
• Parion Sciences
• Par Pharmaceutical
• PediaVision
• Peek Vision
• PeptiDream
• Perelman School of Medicine
• Perrigo
• Pfenex
• Philadelphia VA Medical Center (PVAMC)
• PhotoMedex
• PhysIOL
• Ping An Ventures
• Pixium Vision
• Plex Pharmaceuticals
• Portage Biotech
• Preceyes
• Precision Eye Services
• Precision Lens
• Precision Ocular
• Precision Optics
• Promedica International
• ProQR Therapeutics
• pSivida
• PTC Therapeutics
• Q BioMed
• Q Chip
• Queensland University of Technology
• Queens University Belfast
• Quidel
• R-Tech Ueno
• Recipharm
• Recordati
• Redwood Pharma
• Regeneron Pharmaceuticals
• Regenerx
• ReGenTree
• Regenxbio
• Retina Institute
• RetroSense Therapeutics
• RightEye
• Rising Pharmaceuticals
• River Vision Development
• Roche
• ROCOL
• Rotterdam Eye Hospital
• Rutgers University
• Saban Research Institute of Children's Hospital Los Angeles
• Salus University
• Sam Chun Dang Pharm
• Samsung Bioepis
• Sanofi
• Santen
• Santen Pharmaceutical
• Santhera Pharmaceuticals
• Saphetor
• Sarmedic
• SBI Capital Markets
• Schepens Eye Research Institute
• ScinoPharm Taiwan
• Second Sight Medical
• Selexis
• SemaThera
• Senju Pharmaceutical
• Sequenom
• Shinagawa LASIK Centers
• SIFI (Societa Industria Farmaceutica Italiana)
• Sigenics
• SightLife Surgical
• Simulations Plus
• Singapore Eye Research Institute (SERI)
• Singapore National Eye Centre
• SKS Ocular
• Smile Eyes Group
• Sonoma Pharmaceuticals
• South Coast Specialty Compounding
• Spark Therapeutics
• Specialised Therapeutics
• Staar Surgical Co
• STADA Arzneimittel
• Streetlab
• Sun Pharmaceutical
• SynergEyes
• Synpromics
• Taiwan Liposome Company
• Takeda Pharmaceutical
• Tamid Bio
• Tangible Science
• Targazyme
• TearLab
• Teijin
• Tel Aviv University
• Teleon Surgical
• Temple University
• Tetra Bio-Pharma
• Teva Pharmaceutical Industries
• The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research
• Therakine
• Thomas Jefferson University
• ThromboGenics
• Tilak Healthcare
• Tobii Technology
• Topcon
• TOT BIOPHARM
• Tracey Technologies
• TRACON Pharmaceuticals
• Transitions Optical
• Translational Research Institute for Space Health
• Translatum Medicus
• Trefoil Therapeutics
• TRIGR Therapeutics
• Tu Dresden
• twoXAR
• U.S. First Responders Association
• Ulster University
• Uni-Bio Science
• Unilens Vision
• Unilife
• University City Science Center
• University College London
• University of British Columbia
• University of California
• University of California
• Davis
• University of California
• San Diego
• University of California Berkeley
• University of California Irvine
• University of California San Francisco
• University of Cologne
• University of Colorado
• University of Colorado Denver
• University of Debrecen
• University of Florida
• University of Florida Research Foundation
• University of Hong Kong
• University of Kent
• University of Massachusetts
• University of Massachusetts Medical School
• University of Miami
• University of Nebraska
• University of North Carolina
• University of Oxford
• University of Pennsylvania
• University of Pennsylvania School of Veterinary Medicine
• University of Pittsburgh
• University of Pittsburgh Medical Center
• University of Strathclyde
• University of Washington
• University of Wisconsin
• Upsher-Smith
• Ursapharm
• US Vision
• Valeant Pharmaceuticals
• Vanda Pharmaceuticals
• Vasomune Therapeutics
• Versant Health
• Viela Bio
• Vision Acquisition
• VisionCare Ophthalmic Technologies
• Visioneering Technologies
• VisionQuest Biomedical
• Vista Oftalmlogos
• Vitrisa Therapeutics
• Vivior
• Volk Optical
• Voyant Biotherapeutics
• Vycor Medical
• Wake Forest University
• Washington State University
• Welch Allyn
• Wellcome Trust
• Westminster Pharmaceuticals
• Wize Pharma
• World Eye Hospital
• Xbrane Bioscience
• XL-Protein
• YouHealth Eyetech
• Zizhu Pharma

For more information about this report visit https://www.researchandmarkets.com/r/oylnxb

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com